Virginia Drug Discovery Consortium
The Virginia Drug Discovery Consortium (VaDDC) has a threefold mission:
To promote the growth and advancement of drug discovery and development programs at universities and research institutes within Virginia, particularly through inter-institutional collaboration.
To help the pharmaceutical industry bring life-saving and quality of life solutions to patients through innovative collaborations with Virginia’s best and brightest researchers.
To promote and enhance the attractiveness of Virginia as an environment for pharmaceutical and biotech companies.
Paul Carlier, a professor in the Department of Chemistry in the Virginia Tech College of Science and director of the Virginia Tech Center for Drug Discovery, and his colleagues received a $3.7 million grant from the National Institutes of Health to begin further...
Norwegian researchers have shown that a phosphatase (PRL-3) inhibitor developed by VaDDC Exec. Comm. member John Lazo might be useful to treat cancer
For the first time, researchers have shown how cancer cells reprogram themselves to produce lactic acid and to tolerate the acidic environment that exists around tumors. The finding could lead to a whole new direction for treating cancer. Read More ->
Webster Santos, Virginia Tech drug researcher receives $2.2 million NIH grant to further develop “fat burning” molecule
The Santos lab will use the grant to take his prototype molecules and synthesize derivatives to enhance their effectiveness in treating NASH (nonalcoholic steatohepatitis), which is characterized by inflammation, fat accumulation, and scarring of the liver. Read more...
Want to work with us?
If you are interested in supporting this initiative, please contact us.